X4 Pharmaceuticals Inc

NASDAQ:XFORUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

Contact Information

Headquarters

61 NORTH BEACON STREET, 4TH FLOORBOSTON, MA, United States 02134

Phone

857-529-8300

Fax

302-655-5049

Executives

Non-Executive Independent Chairman of the Board

Michael Wyzga

President, Chief Executive Officer, Secretary, Director

Paula Ragan

Chief Financial Officer, Treasurer, Corporate Secretary

Adam Mostafa

Chief Operating Officer

Mary Dibiase

Chief Scientific Officer

Arthur Taveras